Business Wire

CSG Launches Industry’s First Cloud-based BSS Solution for the Communications Industry

Share

CSG (NASDAQ: CSGS) today introduced Ascendon Communications, the industry’s first software-as-a-service (SaaS)-delivered, cloud-based business support systems (BSS) solution.

Built leveraging Amazon Web Services (AWS), Ascendon Communications is a multi-tenant solution that helps communications service providers (CSPs) retain and expand their customer base, increase revenues by accelerating the launch of new services, support new business model and offering innovation, and reduce costs through a cloud-based architecture.

Ascendon Communications, part of the company’s Ascendon digital monetization solution suite, is delivered as a SaaS, cloud-based platform, so that providers can move purposefully toward modernizing front- and back-office systems, resulting in reduced operating costs associated with launching new digital services and entering new markets.

“The opportunities that the next generation of technology delivers is radically reshaping how communications service providers are formulating their business models and launching new services to keep pace with their competition,” said Chad Dunavant, global head of product management, CSG. “Ascendon is the only solution in the industry giving CSPs the agility to outpace competition with accelerated launches of new services, while reducing cost with cloud-based SaaS deployment models.”

The next-generation, digital BSS solution spans omni-channel user experiences, product and offer catalogs, B2B2x offerings, order management, capture and decomposition, service activation, real-time rating and charging, billing and revenue management, and invoicing.

Key solution features include:

  • A scalable omni-channel experience leveraging a set of open integration APIs
  • Modularized, pluggable component architecture enabling seamless integration to existing platforms
  • The ability to sell traditional and digital services together as a single offering
  • Simultaneously supports pre-paid and post-paid B2C and B2B business models
  • Carrier grade 7x24x365 managed operational model, with 99.99% availability and under 100 millisecond average response time
  • Platform driven through business level configuration for rapid deployment and ongoing adaptation
  • Integrated solution modules to minimize time-to-market and maximize new revenue opportunities across emerging digital services
  • Pay as you grow cloud economics, with virtualization through AWS
  • SaaS benefits including quarterly releases of new out-of-the-box functionality

This new solution is part of multiple market-leading Ascendon deployments to be announced in the coming year, including greenfield projects; consolidation across video, internet and wireline services; and multi-country solutions.

The solution is part of CSG’s Revenue and Customer Management suite of end-to-end capabilities. CSG supports over 500 companies around the world, providing them with flexible and configurable solutions that help them monetize and digitally enable their customer experiences. CSG offers an innovative and evolutionary approach to digital business transformation, helping clients launch digital services quickly, while maintaining their traditional business and delivering an outstanding experience for their customers. CSG’s ability to execute revenue management, digital services monetization and customer experience solutions for its customers has twice resulted in the company being named a leader in the Gartner Magic Quadrant for Integrated Revenue and Customer Management for CSPs.

About CSG

CSG is a provider of software and services that help companies around the world monetize and digitally enable the customer experience. For more than 35 years, CSG has simplified the complexity of business, providing revenue management and digital monetization, payments, and customer engagement solutions to help our customers tackle any business challenge and thrive in an ever-changing marketplace.

Operating across more than 120 countries worldwide, CSG manages billions of critical customer interactions annually. CSG is the trusted partner driving digital innovation for hundreds of leading global brands, including AT&T, Charter Communications, Comcast, DISH, Eastlink, Formula One, iflix, MTN and Telstra.

To learn more, visit our website at csgi.com and connect with us on LinkedIn, Twitter and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brad Jones
Public Relations
CSG
+1 (303) 200-3001
brad.jones@csgi.com

Liz Bauer
Investor Relations
CSG
+1 (303) 804-4065
liz.bauer@csgi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 23:30:00 EEST | Press release

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 23:05:00 EEST | Press release

IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 22:26:00 EEST | Press release

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 22:24:00 EEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 22:08:00 EEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye